Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 10 April 2009:
Vol. 324. no. 5924, pp. 261 - 265
DOI: 10.1126/science.1170944
Prev | Table of Contents | Next

Reports

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1{alpha}

Shimin Zhao,1,2 Yan Lin,1* Wei Xu,1,2* Wenqing Jiang,1,2* Zhengyu Zha,1 Pu Wang,1,2 Wei Yu,1,2 Zhiqiang Li,4 Lingling Gong,5 Yingjie Peng,6 Jianping Ding,6 Qunying Lei,1,3 Kun-Liang Guan,1,3,7{dagger} Yue Xiong1,2,8{dagger}

Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 (IDH1) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown. We have shown that tumor-derived IDH1 mutations impair the enzyme's affinity for its substrate and dominantly inhibit wild-type IDH1 activity through the formation of catalytically inactive heterodimers. Forced expression of mutant IDH1 in cultured cells reduces formation of the enzyme product, {alpha}-ketoglutarate ({alpha}-KG), and increases the levels of hypoxia-inducible factor subunit HIF-1{alpha}, a transcription factor that facilitates tumor growth when oxygen is low and whose stability is regulated by {alpha}-KG. The rise in HIF-1{alpha} levels was reversible by an {alpha}-KG derivative. HIF-1{alpha} levels were higher in human gliomas harboring an IDH1 mutation than in tumors without a mutation. Thus, IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.

1 Molecular and Cell Biology Laboratory, Institute of Biomedical Sciences, Fudan University, 130 Dong-An Road, Shanghai 200032, China.
2 School of Life Sciences, Fudan University, 220 Han-Dan Road, Shanghai 200433, China.
3 Department of Biological Chemistry, School of Medicine, Fudan University, 130 Dong-An Road, Shanghai 200032, China.
4 Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan 430071, China.
5 Department of Pathology, Zhongnan Hospital, Wuhan University, Wuhan 430071, China.
6 State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China.
7 Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
8 Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA.

* These authors contributed equally to this work.

{dagger} To whom correspondence should be addressed. E-mail: kuguan{at}ucsd.edu (K.-L.G.); yxiong{at}email.unc.edu (Y.X.)

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas.
S. Nobusawa, T. Watanabe, P. Kleihues, and H. Ohgaki (2009)
Clin. Cancer Res. 15, 6002-6007
   Abstract »    Full Text »    PDF »
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome.
E. R. Mardis, L. Ding, D. J. Dooling, D. E. Larson, M. D. McLellan, K. Chen, D. C. Koboldt, R. S. Fulton, K. D. Delehaunty, S. D. McGrath, et al. (2009)
N. Engl. J. Med. 361, 1058-1066
   Abstract »    Full Text »    PDF »
Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations.
H. Carter, S. Chen, L. Isik, S. Tyekucheva, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, and R. Karchin (2009)
Cancer Res. 69, 6660-6667
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)